In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp.

Abstract

The in vitro activity of the peptide IB-367, alone or combined with either fluconazole (FLU) or amphotericin B (AMB), was investigated against 25 Candida isolates belonging to five species. IB-367 minimum inhibitory concentrations (MICs) ranged from 2.0 to 32 microg/ml and it was active against both FLU-susceptible and - resistant isolates. A rapid fungicidal activity was observed. Synergism was documented in 41.6% and 44% of IB-367/FLU and IB-367/AMB interactions, respectively. Antagonism was never observed. The broad antifungal activity and the positive interactions with AMB and FLU suggest that IB-367 represents a promising candidate against infections due to Candida spp.

• Authors: F Barchiesi, A Giacometti, O Cirioni, D Arzeni, W Kamysz, C Silvestri, A Licci, A Marigliano, A Della Vittoria, P Nadolski, J Łukasiak, G Scalise
• Journal: Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 19 Issue 5 Pg. 514-8 (Oct 2007) ISSN: 1120-009X [Print] England
• PMID: 18073150 (Publication Type: Journal Article)

Chemical References

• Antifungal Agents
• Antimicrobial Cationic Peptides
• Peptides
• Amphotericin B
• Fluconazole
• antimicrobial peptide IB-367

Topics

• Amphotericin B (administration & dosage)
• Antifungal Agents (pharmacology)
• Antimicrobial Cationic Peptides
• Candida (drug effects)
• Candidiasis (drug therapy)
• Drug Resistance, Fungal
• Drug Synergism
• Drug Therapy, Combination
• Fluconazole (administration & dosage)
• Humans
• In Vitro Techniques
• Microbial Sensitivity Tests
• Peptides (pharmacology)